Renaissance Technologies (RenTech)'s UTMD Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 184,114 shares of Utah Medical Products, Inc. (UTMD) worth $11.41 M, representing 0.02% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in UTMD, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2024, adding 27,900 shares. Largest reduction occurred in Q3 2021, reducing 13,879 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Utah Medical Products (UTMD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Utah Medical Products (UTMD) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -9,500 | Reduce 4.91% | 184,114 | $61.99 |
| Q4 2025 | -7,300 | Reduce 3.63% | 193,614 | $55.96 |
| Q3 2025 | -12,400 | Reduce 5.81% | 200,914 | $62.97 |
| Q2 2025 | -4,400 | Reduce 2.02% | 213,314 | $56.92 |
| Q1 2025 | -3,796 | Reduce 1.71% | 217,714 | $56.04 |
| Q4 2024 | -9,104 | Reduce 3.95% | 221,510 | $61.47 |
| Q3 2024 | +3,500 | Add 1.54% | 230,614 | $66.91 |
| Q2 2024 | -5,400 | Reduce 2.32% | 227,114 | $66.81 |
| Q1 2024 | +27,900 | Add 13.64% | 232,514 | $71.11 |
| Q4 2023 | -900 | Reduce 0.44% | 204,614 | $84.22 |
| Q3 2023 | +2,122 | Add 1.04% | 205,514 | $86.00 |
| Q2 2023 | -3,322 | Reduce 1.61% | 203,392 | $0.09 |
| Q1 2023 | -3,900 | Reduce 1.85% | 206,714 | $0.09 |
| Q4 2022 | -5,900 | Reduce 2.72% | 210,614 | $0.10 |
| Q3 2022 | -10,856 | Reduce 4.77% | 216,514 | $85.31 |
| Q2 2022 | +3,656 | Add 1.63% | 227,370 | $85.90 |
| Q1 2022 | +800 | Add 0.36% | 223,714 | $89.86 |
| Q4 2021 | -7,121 | Reduce 3.10% | 222,914 | $100.00 |
| Q3 2021 | -13,879 | Reduce 5.69% | 230,035 | $92.84 |
| Q2 2021 | -3,000 | Reduce 1.21% | 243,914 | $85.04 |
| Q1 2021 | -823 | Reduce 0.33% | 246,914 | $86.60 |
| Q4 2020 | +6,923 | Add 2.87% | 247,737 | $84.30 |
| Q3 2020 | +7,100 | Add 3.04% | 240,814 | $79.87 |
| Q2 2020 | +2,200 | Add 0.95% | 233,714 | $88.62 |
| Q1 2020 | -2,700 | Reduce 1.15% | 231,514 | $94.05 |
| Q4 2019 | -3,300 | Reduce 1.39% | 234,214 | $107.90 |
| Q3 2019 | -11,000 | Reduce 4.43% | 237,514 | $95.84 |
| Q2 2019 | +10,266 | Add 4.31% | 248,514 | $95.70 |
| Q1 2019 | -966 | Reduce 0.40% | 238,248 | $88.25 |
| Q4 2018 | -11,369 | Reduce 4.54% | 239,214 | $83.08 |
| Q3 2018 | +24,283 | Add 10.73% | 250,583 | $94.20 |
| Q2 2018 | +7,378 | Add 3.37% | 226,300 | $110.15 |
| Q1 2018 | +6,722 | Add 3.17% | 218,922 | $98.85 |
| Q4 2017 | +18,900 | Add 9.78% | 212,200 | $81.40 |
| Q3 2017 | +26,755 | Add 16.06% | 193,300 | $73.55 |
| Q2 2017 | +21,845 | Add 15.10% | 166,545 | $72.40 |
| Q1 2017 | +7,700 | Add 5.62% | 144,700 | $62.30 |
| Q4 2016 | +2,000 | Add 1.48% | 137,000 | $72.75 |
| Q3 2016 | +4,500 | Add 3.45% | 135,000 | $59.80 |
| Q2 2016 | +6,769 | Add 5.47% | 130,500 | $63.00 |
| Q1 2016 | +14,731 | Add 13.51% | 123,731 | $62.54 |
| Q4 2015 | +14,200 | Add 14.98% | 109,000 | $58.54 |
| Q3 2015 | +2,400 | Add 2.60% | 94,800 | $53.87 |
| Q2 2015 | +2,400 | Add 2.67% | 92,400 | $59.63 |
| Q1 2015 | +1,300 | Add 1.47% | 90,000 | $59.86 |
| Q4 2014 | +1,000 | Add 1.14% | 88,700 | $60.05 |
| Q3 2014 | +400 | Add 0.46% | 87,700 | $48.76 |
| Q2 2014 | +7,000 | Add 8.72% | 87,300 | $51.44 |
| Q1 2014 | +4,900 | Add 6.50% | 80,300 | $57.83 |
| Q4 2013 | +7,300 | Add 10.72% | 75,400 | $57.16 |
| Q3 2013 | +13,400 | Add 24.50% | 68,100 | $59.44 |
| Q2 2013 | +54,700 | Add 0.00% | 54,700 | $54.30 |
Renaissance Technologies (RenTech)'s Utah Medical Products Investment FAQs
Renaissance Technologies (RenTech) first purchased Utah Medical Products, Inc. (UTMD) in Q2 2013, acquiring 54,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Utah Medical Products, Inc. (UTMD) for 52 quarters since Q2 2013.
Renaissance Technologies (RenTech)'s largest addition to Utah Medical Products, Inc. (UTMD) was in Q2 2013, adding 54,700 shares worth $2.97 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 184,114 shares of Utah Medical Products, Inc. (UTMD), valued at approximately $11.41 M.
As of the Q1 2026 filing, Utah Medical Products, Inc. (UTMD) represents approximately 0.02% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Utah Medical Products, Inc. (UTMD) was 250,583 shares, as reported at the end of Q3 2018.